Type your tag names separated by a space and hit enter

Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients.

Abstract

PURPOSE

Despite the widespread use of antiemetics, nausea continues to be reported by over 70% of patients receiving chemotherapy.

METHODS

In this double blind, multicenter trial, we randomly assigned 744 cancer patients to four arms: 1) placebo, 2) 0.5 g ginger, 3) 1.0 g ginger, or 4) 1.5 g ginger. Nausea occurrence and severity were assessed at a baseline cycle and the two following cycles during which patients were taking their assigned study medication. All patients received a 5-HT(3) receptor antagonist antiemetic on Day 1 of all cycles. Patients took three capsules of ginger (250 mg) or placebo twice daily for 6 days starting 3 days before the first day of chemotherapy. Patients reported the severity of nausea on a 7-point rating scale ("1" = "Not at all Nauseated" and "7" = "Extremely Nauseated") for Days 1-4 of each cycle. The primary outcomes were to determine the dose and efficacy of ginger at reducing the severity of chemotherapy-induced nausea on Day 1 of chemotherapy.

RESULTS

A total of 576 patients were included in final analysis (91% female, mean age = 53). Mixed model analyses demonstrated that all doses of ginger significantly reduced acute nausea severity compared to placebo on Day 1 of chemotherapy (p = 0.003). The largest reduction in nausea intensity occurred with 0.5 g and 1.0 g of ginger (p = 0.017 and p = 0.036, respectively). Anticipatory nausea was a key factor in acute chemotherapy-induced nausea (p < 0.0001).

CONCLUSIONS

Ginger supplementation at a daily dose of 0.5 g-1.0 g significantly aids in reduction of the severity of acute chemotherapy-induced nausea in adult cancer patients.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Departments of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY 14642, USA. julie_ryan@urmc.rochester.edu

    , , , , , ,

    Source

    MeSH

    Antiemetics
    Antineoplastic Agents
    Dose-Response Relationship, Drug
    Double-Blind Method
    Female
    Ginger
    Humans
    Male
    Middle Aged
    Nausea
    Neoplasms
    Phytotherapy
    Serotonin 5-HT3 Receptor Antagonists
    Severity of Illness Index
    Treatment Outcome
    Vomiting
    Vomiting, Anticipatory

    Pub Type(s)

    Clinical Trial, Phase II
    Clinical Trial, Phase III
    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, N.I.H., Extramural

    Language

    eng

    PubMed ID

    21818642

    Citation

    Ryan, Julie L., et al. "Ginger (Zingiber Officinale) Reduces Acute Chemotherapy-induced Nausea: a URCC CCOP Study of 576 Patients." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, vol. 20, no. 7, 2012, pp. 1479-89.
    Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20(7):1479-89.
    Ryan, J. L., Heckler, C. E., Roscoe, J. A., Dakhil, S. R., Kirshner, J., Flynn, P. J., ... Morrow, G. R. (2012). Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 20(7), pp. 1479-89. doi:10.1007/s00520-011-1236-3.
    Ryan JL, et al. Ginger (Zingiber Officinale) Reduces Acute Chemotherapy-induced Nausea: a URCC CCOP Study of 576 Patients. Support Care Cancer. 2012;20(7):1479-89. PubMed PMID: 21818642.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. AU - Ryan,Julie L, AU - Heckler,Charles E, AU - Roscoe,Joseph A, AU - Dakhil,Shaker R, AU - Kirshner,Jeffrey, AU - Flynn,Patrick J, AU - Hickok,Jane T, AU - Morrow,Gary R, Y1 - 2011/08/05/ PY - 2011/03/14/received PY - 2011/07/15/accepted PY - 2011/8/6/entrez PY - 2011/8/6/pubmed PY - 2012/10/23/medline SP - 1479 EP - 89 JF - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JO - Support Care Cancer VL - 20 IS - 7 N2 - PURPOSE: Despite the widespread use of antiemetics, nausea continues to be reported by over 70% of patients receiving chemotherapy. METHODS: In this double blind, multicenter trial, we randomly assigned 744 cancer patients to four arms: 1) placebo, 2) 0.5 g ginger, 3) 1.0 g ginger, or 4) 1.5 g ginger. Nausea occurrence and severity were assessed at a baseline cycle and the two following cycles during which patients were taking their assigned study medication. All patients received a 5-HT(3) receptor antagonist antiemetic on Day 1 of all cycles. Patients took three capsules of ginger (250 mg) or placebo twice daily for 6 days starting 3 days before the first day of chemotherapy. Patients reported the severity of nausea on a 7-point rating scale ("1" = "Not at all Nauseated" and "7" = "Extremely Nauseated") for Days 1-4 of each cycle. The primary outcomes were to determine the dose and efficacy of ginger at reducing the severity of chemotherapy-induced nausea on Day 1 of chemotherapy. RESULTS: A total of 576 patients were included in final analysis (91% female, mean age = 53). Mixed model analyses demonstrated that all doses of ginger significantly reduced acute nausea severity compared to placebo on Day 1 of chemotherapy (p = 0.003). The largest reduction in nausea intensity occurred with 0.5 g and 1.0 g of ginger (p = 0.017 and p = 0.036, respectively). Anticipatory nausea was a key factor in acute chemotherapy-induced nausea (p < 0.0001). CONCLUSIONS: Ginger supplementation at a daily dose of 0.5 g-1.0 g significantly aids in reduction of the severity of acute chemotherapy-induced nausea in adult cancer patients. SN - 1433-7339 UR - https://www.unboundmedicine.com/medline/citation/21818642/full_citation L2 - https://dx.doi.org/10.1007/s00520-011-1236-3 DB - PRIME DP - Unbound Medicine ER -